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Mannose-Binding Lectin (MBL) is a prognostic marker in pulmonary diseases. Ficolins, sharing
many structural and functional similarities with MBL, may also be involved in the pathogenesis
of pulmonary diseases.
The objectives of the study were to establish whether plasma concentrations of Ficolin-2, -3,
and MBL in Danish patients with sarcoidosis and control persons differed and whether they were
of prognostic significance.
We retrospectively included 46 consecutive patients (26 male, 20 female) and 51 age- and
sex-matched healthy control persons (28 male, 23 female). Information about the patients was
obtained from their medical records. We measured plasma concentrations of Ficolin-2, -3, and
MBL using ELISA.
There was a significant difference in the patients’ mean Ficolin-3 plasma level (14.9 mg/ml;
2SD: 6.7e 23.1) compared with the control persons’ (21.6 mg/ml; 2SD: 12.7e 30.5). The dif-
ference was 6.7 mg/ml (95% CI: 5.0e8.4 mg/ml; p< 0.001). In the patients, Ficolin-3 correlated68 38 98; fax: þ45 32 68 38 73.
endsen).
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1238 C.B. Svendsen et al.inversely with the CD4þ/CD8þ-ratio (Spearman’s RhoZ0.37; pZ 0.021; nZ 39). There were
no significant differences in plasma concentrations of Ficolin-2 or MBL between the two groups.
Ficolin-3 concentrations were lower in plasma from patients with sarcoidosis. This suggests
a possible involvement of Ficolin-3 in the complex pathophysiology of sarcoidosis. However, we
could not show the applicability of Ficolin plasma level measurement as a marker of disease ac-
tivity or of prognostic significance in sarcoidosis.
ª 2008 Elsevier Ltd. All rights reserved.Table 1 Characteristics of the study population
Patient
group
(nZ 46)
Control
group
(nZ 51)
Sex
Male 26 28
Female 20 23
Age mean (2 SD) (y) 41 (18e63) 42 (19e65)
Tobacco smoking habitsa
N/Ab (%) 11 (nZ 5) N/Ab
Never smoked (%) 35 (nZ 16) N/Ab
Less than 10 pack years (%) 24 (nZ 11) N/Ab
10-20 pack years (%) 17 (nZ 8) N/Ab
More than 20 pack years (%) 13 (nZ 6) N/Ab
Disease duration median
(IQRc) (y)
8.0 (1.7e16.2) N/Ab
a One pack year refers to 20 cigarettes per day for a year.
b N/AZ information not available.
c IQRZ interquartile range.Introduction
Sarcoidosis is a chronic, granulomatous disease of unknown
origin. It is assumed to be due to an inappropriate immune
response to one or more unknown antigen(s) in genetically
predisposed individuals.1 The genetic aspect of the patho-
genesis accounts for approximately 2/3 of the susceptibility
to the development of sarcoidosis.2 The hypothesised ex-
ternal eliciting antigens are primarily bacterial,3e5 but
other organic as well as inorganic compounds have been
suggested, and recently nanoparticles have been claimed
to be involved.6 A common characteristic of the suggested
antigens is their ability to enter the body through either the
skin or the lungs. Both the cellular and humoral immune re-
sponses are affected in sarcoidosis, and the formation of
the sarcoid granulomas is primarily driven by a macrophage
and T helper cell 1 (Th1) response.7
Ficolin-2 (L-Ficolin), Ficolin-3 (H-Ficolin, Hakata anti-
gen), and Mannose-Binding Lectin (MBL) are soluble pattern
recognition molecules that recognise carbohydrate or
acetyl-group containing ligands. Following recognition,
they can activate the complement system.8 They are all
able to form complexes with MBL-associated serine prote-
ases (MASPs) and an MBL-associated protein (MAp19).8
The complement system is suggested to be involved in
sarcoidosis.9Likewise,apoptosisgenes (theBcl-2 family)areup-
regulated in patients with sarcoidosis.10 Both Ficolin-2, -3 and
MBL are involved in the clearance of apoptotic cells, andwe hy-
pothesisethatthesarcoidresponsecouldpartlybeduetodimin-
ishedactivity in theseproteins, leading to impairedclearanceof
apoptotic cells and/or antigens from the tissue.11e13
Other studies have found the MBL gene polymorphisms
to be a prognostic marker for exacerbations in chronic pul-
monary disease.14 A study on MBL relating to sarcoidosis
looked for genetic variants in the coding region of the
MBL2 gene in patients with sarcoidosis compared with con-
trol persons and did not find any significant differences be-
tween the two groups.15 Although MBL has been studied
genetically, this is the first report on plasma levels of MBL
in patients with sarcoidosis.
The purpose of this study was to investigate whether
plasma concentrations of MBL, Ficolin-2 and -3 were
affected in patients with clinically overt sarcoidosis.
Furthermore, it was investigated if any of these compo-
nents could be used as prognostic markers in patients with
sarcoidosis and whether they had any correlation with:
chest X-ray disease stage1; disease activity; disease dura-
tion; prednisolone treatment; pulmonary function tests;
CD4þ/CD8þ-ratio; and biochemical activity markers, such
as serum angiotensin converting enzyme (ACE), serumsoluble interleukin-2 receptor (sIL-2R), and plasma concen-
trations of immunoglobulins (Ig-) G, IgM and IgA.Material and methods
The study was approved by the Regional Medical Ethics
Committee (No. KF 01 303797) and the Danish Data Pro-
tection Agency (No. 2006-41-6575). Informed consent was
obtained from all participating subjects.Study subjects and design
We retrospectively enrolled 49 consecutive sarcoidosis
patients from the Lung Clinic at Rigshospitalet in Copenha-
gen (Table 1). Forty-six were ethnic Danish patients; two
patients of African and one patient of Middle Eastern heri-
tage were excluded. Thirty-six patients had a biopsy-
proven diagnosis and 10 patients had their diagnosis made
by typical clinical and paraclinical findings. Mycobacteriosis
was ruled out by special stains in all biopsy-proven cases
and/or polymerase chain reaction (PCR)/culture for myco-
bacteria from bronchoalveolar lavage fluid or sputum in 23
patients. The patients were staged with respect to their
disease according to the European Respiratory Society
guidelines using their most recent chest X-ray.1
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recruited from the Blood Bank, Department of Clinical
Immunology at Rigshospitalet in Copenhagen, age- and sex-
matched to the patient group (Table 1).
Methods
From the patients and control persons, a convenience sam-
ple of EDTA-plasma was available. Ficolin-2, -3, and MBL
concentrations were, therefore, measured in EDTA-plasma.
We have previously shown that Ficolin concentrations can be
measured in samples of EDTA-plasma, heparinised plasma,
citrate plasma and serum with similar values obtained.16,17
Medical records were scrutinized for information on labora-
tory analyses, histopathology, pulmonary function tests, ra-
diological findings, prednisolone treatment, and symptoms.
For Ficolin-2 and -3, we used ELISA assays as previously
described.16,17 Heterophilic anti-animal antibodies or rheu-
matoid factors may exist in the plasma sample, reacting
with the capture antibody and subsequently with the de-
tection antibody. This can cause erroneous high signals.18
We, therefore, performed a control assay, in which a mouse
monoclonal antibody of identical subclass and light chain
type in the same concentration with no known specificity
replaced the capture antibody.
We measured MBL concentrations by a sandwich ELISA
performed essentially as described previously.19 Briefly,
MBL was quantified by a semi-automated time-resolved im-
munofluorescence assay using the monoclonal antibody Hyb
131-01 (Statens Serum Institut, Copenhagen, Denmark) as
catcher, biotinylated Hyb 131-01 as detector, and streptavi-
din-Eu-chelate for quantification. The assay was run on an
AutoDelphia platform (Perkin Elmer, Shelton, CT, USA).
The method had a lower cut-off of 10 mg/l and samples
with a concentration below cut-off were denoted < 10 mg/l.
Results from pulmonary function tests, S-ACE, S-sIL-2R,
P-Immunoglobulins, and blood leukocyte CD4þ/CD8þ-ratios
were obtained from the medical records. Pulmonary func-
tion tests were performed on a Jaeger MasterScreen
Body (E. Jaeger GmbH, Wu¨rzburg, Germany). Serum-ACE
was measured using a direct spectrophotometric assay.
Serum-sIL-2R was measured using enzyme-enhanced chem-
iluminescence on an IMMULITE 2000 (Siemens Medical
Solutions Diagnostics, Los Angeles, CA, USA). Immunoglobu-
lin levels were determined using routine laboratory
methods. Blood leukocyte CD4þ/CD8þ-ratios were deter-
mined using a Bechman-Coulter Epics XL flow cytometer.Table 2 Variations of Ficolin-2, -3, and Mannose-Binding Lectin
Group n Mean (mg/m
Ficolin-2 Controls 51 3.54
Patients 46 3.17
Ficolin-3 Controls 51 21.6
Patients 46 14.9
Group n Median (mg/
Mannose-Binding Lectin (MBL) Controls 51 673
Patients 46 821
Only ethnic Danish patients included.Analysis
We performed the statistical analyses using SPSS 15.0 for
Windows (Release 15.0.1.1 (July 3, 2007), Copyrightª SPSS
Inc.). We analysed values for patients of ethnic Danish her-
itage only. We compared Ficolin-2, -3, IgG, and IgA concen-
trations between groups using the two-sample t test for
unpaired data. We used the ManneWhitney U test for the
comparisons including: pulmonary function markers, MBL,
ACE, sIL-2R, IgM, and CD4þ/CD8þ-ratio due to lack of Nor-
mal distribution. The effect of smoking status on the
plasma levels of Ficolin-2, Ficolin-3 and MBL was analysed
both as a one-way analysis of variance (ANOVA) with a Bon-
ferroni correction for multiple comparisons on the strata
shown in Table 2 and as a comparison between smoker/
never-smoker using the two-sample t test or ManneWhitney
U test as applicable. We used Spearman’s Rho for correla-
tions between variables. We used a Pearson’s chi-square
test or Fisher’s exact test for contingency tables where ap-
plicable. For MBL comparisons, we recoded samples with
a concentration of <10 mg/l as 5 mg/l to avoid left-censored
data. Significance level was set at pZ 0.05 (2-tailed), non-
significant comparisons are marked NS.Results
The results are summarised in Tables 1, 2 and 3 and se-
lected associations are shown in Fig. 1. The three patients
of noneDanish heritage were excluded from the analyses,
since extreme values of MBL, Ficolin-2, and -3 were found
compared to the ethnic Danish patients.
There was a significant tendency among our patients
towards the men having more advanced disease than the
women at the time of the investigation (Table 3, pZ 0.017).
The patients had a mean level of plasma Ficolin-3 of
14.9 mg/ml (2SD: 6.7e 23.1) compared to 21.6 mg/ml
(2SD: 12.7e 30.5) in the control group (Fig. 1B). The dif-
ference between the two groups was 6.7 mg/ml (95% CI:
5.0e8.4 mg/ml; p< 0.001). There was no significant differ-
ence in plasma levels of Ficolin-2 or MBL between the two
groups (Fig. 1A and C). No heterophilic antibodies were
found in any of the samples.
Ficolin-3 correlated inversely with the blood lymphocyte
CD4þ/CD8þ-ratio within the patient group (Spearman’s
RhoZ0.37; pZ 0.021; nZ 39) (Fig. 1D). Moreover, Fico-
lin-3 correlated with Ficolin-2 (Spearman’s RhoZ 0.43;between the groups
l) SD (mg/ml) S.E. of mean (mg/ml) p value
1.00 0.14 0.074
1.04 0.15
4.46 0.63 <0.001
4.08 0.64
l) 1st Quartile (mg/l) 3rd Quartile (mg/l) p value
150 1566 0.226
256 2286
Table 3 Difference in the distribution of male and female
subjects between different disease stages
Gender Total
m f n %
Radiological stage (1)
N/Aa 1 0 1 2
0 2 6 8 17
I 0 3 3 7
II 1 0 1 2
III 6 3 9 20
IV 16 8 24 52
Total (n) 26 20 46 100
Only ethnic Danish patients included.
Fisher’s exact test; pZ 0.042.
a N/AZ information not available.
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lin-3 and: age, radiological disease stage, prednisolone
treatment (treated vs. untreated), disease duration, ACE,
sIL-2R, immunoglobulin levels, or pulmonary function tests.
Smoking status did not influence the Ficolin-3 concentra-
tions significantly (One-way ANOVA, pZ 0.6, two-sample t
test; smokers vs. never-smokers, pZ 0.12).Figure 1 Selected comparisons between groups, only ethnic Dani
control persons. B. Ficolin-3 concentrations in patients vs. control
vs. control persons. D. Scatter plot of the association between FicFicolin-2 and MBL correlated positively with each other
among the patients (Spearman’s RhoZ 0.30; pZ 0.041;
nZ 46). They did not correlate significantly with any of
the other investigated clinical parameters and neither
smoking status (smokers vs. never-smokers) nor predniso-
lone treatment (treated vs. untreated) had a statistically
significant effect on these.Discussion
The mean plasma concentration of Ficolin-3 was signifi-
cantly lower in the patients with sarcoidosis than in the
control persons. Ficolin-3 is highly expressed in the lung and
liver.20,21 Which of these compartments that contributes
most to the plasma level, is unknown. The reduced plasma
concentration could be explained by either: (a) reduced
FCN3 expression in the lung and liver due to specific inhib-
itory transcriptional signals or (b) a reduced number of cells
able to produce Ficolin-3. Another, but not mutually exclu-
sive, possibility could be that Ficolin-3 is consumed due to
disease processes in sarcoidosis. A fourth possibility could
be that the low plasma level is due to genetic polymor-
phisms in the FCN3 gene occurring more frequently in sar-
coidosis patients than in the healthy subjects. This issh patients included. A. Ficolin-2 concentrations in patients vs.
persons. C. Mannose-Binding Lectin concentrations in patients
olin-3 and CD4þ/CD8þ-ratio.
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ever, recent studies in our laboratory show that the spec-
trum of polymorphisms in the FCN3 gene is very
restricted.17 Unfortunately, our setup did not include col-
lection of DNA from the patients and the blood samples
were not drawn and treated to enable us to measure com-
plement activation, hence these issues could not be further
explored in the present study.
Ficolin-3 was originally discovered as an autoantigen
under the name Hakata antigen in SLE patients,22 and we
cannot exclude that the reduced levels of Ficolin-3 were
due to autoantibodies to the protein. Whether such anti-
bodies exist in patients with sarcoidosis is unknown and
we did not measure these.
In our study, we did not find a statistically significant
effect of prednisolone treatment on either of the measured
protein levels (data not shown). To our knowledge, there
are no previously published studies showing an effect of
steroids on the levels of Ficolins in plasma, why predniso-
lone treatment is not a likely explanation to the observed
difference.
Nevertheless, the resulting low concentration of Ficolin-
3 in plasma may impair the putative role of Ficolin-3 as an
opsonin. It has previously been shown that Ficolin-3 binds
to and sequesters endogenous waste material such as late
apoptotic cells and cellular debris.11 This could explain the
persistence of environmental antigens suggested to be part
of the pathogenesis of sarcoidosis.
The inverse correlation of Ficolin-3 with blood lympho-
cyte CD4þ/CD8þ-ratio cannot be sufficiently explained by
this setup. Possible explanations include either the activa-
tion of a Th1 response causing the increased CD4þ/CD8þ-
ratio leading to consumption of Ficolin-3 or an inherently
low concentration of Ficolin-3 is compensated by a more
active Th1 response. This should be further investigated.
Sarcoidosis occurs more commonly in non-smokers than
in smokers.1 The concentrations of the Ficolins are not
known to be influenced by tobacco smoking status. How-
ever, the concentrations in the blood and BAL fluid of other
collagen-like defence molecules such as MBL, surfactant
protein A and D are known to be affected by tobacco smo-
king.23e25 We did not have information on tobacco smoking
status in our control group. An ANOVA of the Ficolin-3 levels
within the patient group, stratified by tobacco smoking sta-
tus, as well as analysing smoking status as a dichotomised
variable revealed no significant effect of smoking. This
makes different tobacco smoking patterns in the two
groups an unlikely explanation of the difference.
We found a positive correlation among the patients
between Ficolin-2 and MBL concentrations. This correlation
may be coincidental and possible explanations are specu-
lative. Should the patients have a defective function of the
Ficolin-3 mediated opsonisation, possibly the two other
systems investigated in this study (Ficolin-2 and MBL) could
be upregulated.
In this study, there was no difference in the MBL levels
between the two groups. We found no association between
MBL levels and radiological disease stage or biochemical
disease markers such as S-ACE, serum-sIL-2R, or plasma
immunoglobulin levels. Our finding is in agreement with the
only other published study on MBL in patients with
sarcoidosis.15The present study opens up new perspectives in the
complex pathogenesis of sarcoidosis. The mechanisms
behind the reductions in Ficolin-3 plasma concentrations
remain to be investigated. We could not correlate the
plasma level of either of the proteins to known disease
activity markers, which suggests that Ficolin plasma levels
are not applicable as markers of disease activity, pro-
gression or prognosis given the current evidence. However,
further studies with measurements of Ficolin-3 concentra-
tion in BAL fluid, as well as mRNA levels in the lungs may
provide a more detailed insight into the function of Ficolin-
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